alirocumab

Showing 5 posts of 5 posts found.

Praluent

Sanofi and Regeneron given European nod for Praluent

September 28, 2015
Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent

The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent.  The heart drug is …

ESC congress sign

NHS looks to ESC for next-gen heart drug data

August 28, 2015
Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent

New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …

Sanofi image

Sanofi and Amgen cholesterol drugs shine

March 16, 2015
Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent

Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …

Sanofi image

Sanofi showcases alirocumab at AHA

November 20, 2014
Sales and Marketing Amgen, PCSK9, Regeneron, Sanofi, aha, alirocumab, evolocumab

Sanofi and Regeneron released a battery of new Phase III data on their PCSK9 inhibitor alirocumab this week, reinforcing the …

Regeneron image

Phase III boost for alirocumab

October 17, 2013
Sales and Marketing LDL, Regeneron, alirocumab

Sanofi and Regeneron Pharmaceuticals are celebrating some upbeat data from their investigational treatment alirocumab, which has proved adept at tackling …

Latest content